James Rubec

A chart that shows how Novo Nordisk and Eli Lilly are competing for reach. Periodically Eli Lilly beats Novo Nordisk, but its coverage is less prominent, with Novo Nordisk being dominant in most articles.

They've got risks, including drug pricing, equity concerns, supply shortages, and compound pharmacies creating inferior or incorrect products. Still, Eli Lilly is on their heels, and from a reach perspective, the media loves an underdog.

If a market doesn't have competition, it isn't a market.

A share of voice chart which depicts Novo Nordisk with 70% Share of Voice over Eli Lilly, AstraZeneca, Roche and Sanofi. (10%, 2.98%, 1.23%, and 1.16% for the other competitors)

So I've been tracking the media converstaions around anti-obesity drugs and diabetes medications for the last year. To put it mildly, Novo Nordisk has taken the entire drug market to the woodshed and has been dealing with its competition accordingly. #PR #Data

a white circle with two red triangles in the middle on a black background . ALT: a white circle with two red triangles in the middle on a black background .

Me trying to get back into running and fitness, then travelling for work and throwing my whole schedule off. sigh.

Oh Really? Now they have regrets.

Seconded on The Last Dinner Party, that album is full of bangers.

My Lady of Mercy is a true generational banger, Nothing Matters is a tremendous hook. Soooo good.

This show will be lit! The Last Dinner Party rocks harder than any band since Rush.

#RockOn

I just found this show, hopefully more people dig into it and all its brilliance.

Spanish X-Files leaves it all out on the field.

I'm on the final stages of moving off of the hell-site, now all I need to figure out is how to ingest an API of BlueSky data into different places and the world's my oyster.

How's the air over here?